2019
NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS
Mureb M, Jain R, Poisson L, Littig I, Neto L, Wu C, Ng V, Patel S, Patel S, Serrano J, Kurz S, Cahill D, Bendszus M, von Deimling A, Placantonakis D, Golfinos J, Kickingereder P, Snuderl M, Chi A. NIMG-09. NONINVASIVE PERFUSION IMAGING BIOMARKER OF MALIGNANT GENOTYPE IN ISOCITRATE DEHYDROGENASE MUTANT GLIOMAS. Neuro-Oncology 2019, 21: vi163-vi163. PMCID: PMC6847952, DOI: 10.1093/neuonc/noz175.681.Peer-Reviewed Original ResearchCDKN2A/B homozygous deletionCopy number variationsHomozygous deletionHigher rCBVGenomic alterationsRelative cerebral blood volumeImmediate postoperative settingHigh perfusion areaCopy number statusCerebral blood volumeNon-invasive imaging biomarkerInformed treatment decisionsMalignant genotypePostoperative settingIDHwt glioblastomasRCBVCDKN2A/BIDHmutCNV analysisAstrocytomaBlood volumeTreatment decisionsPerfusion areaImaging biomarkersDNA hypomethylation
2018
GENE-16. CLINICALLY AGGRESSIVE MENINGIOMAS ARE CHARACTERIZED BY MUTATIONAL SIGNATURES ASSOCIATED WITH DEFECTIVE DNA REPAIR AND MUTATIONS IN CHROMATIN REMODELING GENES
Kurz S, Liechty B, Kelly S, Vasudevaraja V, Bledea R, Wu P, Serrano J, Katz L, Silverman J, Pacione D, Golfinos J, Chi A, Snuderl M. GENE-16. CLINICALLY AGGRESSIVE MENINGIOMAS ARE CHARACTERIZED BY MUTATIONAL SIGNATURES ASSOCIATED WITH DEFECTIVE DNA REPAIR AND MUTATIONS IN CHROMATIN REMODELING GENES. Neuro-Oncology 2018, 20: vi106-vi106. PMCID: PMC6216611, DOI: 10.1093/neuonc/noy148.442.Peer-Reviewed Original ResearchSingle nucleotide variantsChromatin remodeling genesCancer-associated genesDefective DNA repairChromatin remodelingAggressive meningiomasMutational signaturesDNA repairIncreased copy number variationDNA methylation array analysisSomatic mutationsRemodeling genesClinically aggressive meningiomasUnfavorable clinical courseAssociated with more aggressive behaviorCopy number variationsPattern of somatic mutationsWhole-exome sequencingMethylation array analysisDNA methylation phenotypeMedian PFSNucleotide variantsAggressive tumorsClinical courseRecurrence rate